[go: up one dir, main page]

MX2022001144A - Metodos y composiciones para modular la microbiota intestinal y para manejar el peso. - Google Patents

Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.

Info

Publication number
MX2022001144A
MX2022001144A MX2022001144A MX2022001144A MX2022001144A MX 2022001144 A MX2022001144 A MX 2022001144A MX 2022001144 A MX2022001144 A MX 2022001144A MX 2022001144 A MX2022001144 A MX 2022001144A MX 2022001144 A MX2022001144 A MX 2022001144A
Authority
MX
Mexico
Prior art keywords
subject
methods
compositions
modulate
intestinal microbiota
Prior art date
Application number
MX2022001144A
Other languages
English (en)
Inventor
Hasan Celiker
Original Assignee
Xeno Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xeno Biosciences Inc filed Critical Xeno Biosciences Inc
Publication of MX2022001144A publication Critical patent/MX2022001144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen métodos para el manejo del peso de un sujeto. Generalmente los métodos comprenden: la administración de una cantidad efectiva al intestino delgado y/o intestino grueso del sujeto de cuando menos un agente que aumenta la tensión del oxígeno y/o el potencial redox y/o el pH en el colon del sujeto para de esta forma manejar el peso de dicho sujeto. También se proveen composiciones que comprenden cuando menos un agente que aumenta la tensión del oxígeno y/o el potencial redox y/o el pH, en donde la composición se formula para la liberación de una cantidad efectiva del cuando menos un agente al intestino delgado y/o al intestino grueso de un sujeto en seguida a la administración oral de la composición al sujeto.
MX2022001144A 2015-06-01 2017-11-28 Metodos y composiciones para modular la microbiota intestinal y para manejar el peso. MX2022001144A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169480P 2015-06-01 2015-06-01
US201662327283P 2016-04-25 2016-04-25

Publications (1)

Publication Number Publication Date
MX2022001144A true MX2022001144A (es) 2022-02-16

Family

ID=57441825

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017015247A MX391477B (es) 2015-06-01 2016-05-31 Metodos y composiciones para modular la microbiota intestinal y para manejar el peso
MX2021011982A MX2021011982A (es) 2015-06-01 2017-11-28 Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
MX2022001144A MX2022001144A (es) 2015-06-01 2017-11-28 Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017015247A MX391477B (es) 2015-06-01 2016-05-31 Metodos y composiciones para modular la microbiota intestinal y para manejar el peso
MX2021011982A MX2021011982A (es) 2015-06-01 2017-11-28 Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.

Country Status (8)

Country Link
US (5) US10945974B2 (es)
EP (2) EP3302703B1 (es)
CN (1) CN107921073B (es)
AU (1) AU2016271303C1 (es)
CA (1) CA2987863A1 (es)
ES (1) ES2898930T3 (es)
MX (3) MX391477B (es)
WO (1) WO2016196440A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016070151A1 (en) 2014-10-31 2016-05-06 Whole Biome. Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
CN107921073B (zh) * 2015-06-01 2022-10-18 塞诺生物科学股份有限公司 用于调节肠道微生物群及管理体重的方法和组合物
CN110520111B (zh) * 2016-11-30 2023-12-19 塞诺生物科学股份有限公司 用以管理体重和调节肠道微生物群的药物制剂和方法
WO2018202897A1 (en) * 2017-05-04 2018-11-08 Schaub Walter Compositions and treatment procedures for the treatment of pathogenic infections
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
CN111202066B (zh) * 2020-02-24 2024-06-14 黑龙江森工农化有限公司 一种使用包覆技术生产的影响鼠类消化系统的无毒诱饵
KR20220163450A (ko) 2020-04-03 2022-12-09 엘폭시 세라퓨틱스 인코퍼레이티드 장 호기화 요법
GB2609445A (en) * 2021-07-30 2023-02-08 Glasport Bio Ltd Compositions and methods
KR20240095216A (ko) * 2021-09-29 2024-06-25 엘폭시 세라퓨틱스 인코퍼레이티드 장 호기화 요법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE425593B (sv) * 1977-08-18 1982-10-18 Astra Ewos Ab Forfarande for framstellning av en farmaceutisk beredning med antibakteriell effekt
US5000869A (en) 1990-02-14 1991-03-19 Safe Aid Products, Inc. Novel polymer coated bleaching composition
DE4109953A1 (de) 1991-03-26 1992-10-01 Henkel Kgaa Lagerstabil verkapseltes partikulaeres natriumpercarbnat und verfahren zu seiner herstellung
US5759539A (en) 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
AU778646B2 (en) 1999-09-09 2004-12-16 Discus Dental, Llc Increased peroxide content tooth bleaching gel
EP1267812B1 (en) 2000-03-17 2009-01-28 LG Household & Health Care Ltd. Patches for teeth whitening
CA2431205C (en) * 2000-12-05 2005-08-23 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
AU2003288988A1 (en) 2002-11-29 2004-06-23 Freund Corporation Water-based shellac coating material, process for producing the same, coated food obtained with the coating material, process for producing the same, coated medicine, process for producing the same, glazing composition for oily snack, method of glazing, and glazed oily snack
JP2004228314A (ja) * 2003-01-22 2004-08-12 Renesas Technology Corp パッドを有する半導体装置
WO2004103303A2 (en) 2003-05-16 2004-12-02 Britesmile Development, Inc. Therapeutic dental composition
US20090016963A1 (en) * 2003-10-22 2009-01-15 Dalia Cohen Genes involved in neurodegenerative conditions
BRPI0509271A (pt) * 2004-03-26 2007-09-04 Lek Pharmaceuticals formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
JP2005336072A (ja) 2004-05-25 2005-12-08 Combi Corp 腎障害抑制剤
AR051946A1 (es) 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
MX2007012220A (es) * 2005-04-06 2007-12-06 Mallinckrodt Inc Formulacion farmaceutica de liberacion por pulsos a base de matriz.
JP2008542255A (ja) 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US20090169630A1 (en) * 2006-05-15 2009-07-02 Kevin Ward Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
US20100092550A1 (en) 2008-10-14 2010-04-15 Nelson Cabral Alka-eeze
BRPI0921577B1 (pt) 2008-11-18 2018-01-30 Gelesis Llc Métodos e composições para controle de peso e para aperfeiçoar controle glicêmico
BRPI1006287A2 (pt) 2009-03-04 2015-08-25 Metaactiv Inc Composição botânica e aditivada por local, método de tratamento prevenção ou aperfeiçoamento dos sintomas de um distúrbio gástrico, método de tratamento da água potável, de uma infecção, de uma ferida, de desinfecção de uma superfície, de preservação de um alimento, e, de melhora da função gástrica de um animal; e kit
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
WO2011002972A2 (en) 2009-07-02 2011-01-06 Hercules Incorporated Stable shellac enteric coating formulation for nutraceutical and pharmaceutical dosage forms
US9642687B2 (en) * 2010-06-15 2017-05-09 The Procter & Gamble Company Methods for whitening teeth
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
ES2540828T3 (es) 2010-09-02 2015-07-13 Naturland Magyarország Termelö És Kereskedelmi Kft. Preparación aplicable por vía peroral que contiene histaminasa de origen vegetal, resistente a pepsina y tripsina y un procedimiento para producirla
US9878020B2 (en) 2011-04-07 2018-01-30 Histapharm Inc. Oral enzyme compositions for intestinal delivery
WO2012177799A1 (en) * 2011-06-20 2012-12-27 Atheronova Operations, Inc. Subcutaneous fat reduction
US8722040B2 (en) * 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
WO2013032744A2 (en) * 2011-08-17 2013-03-07 Nume Health, Llc Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum
WO2013093877A2 (en) 2011-12-23 2013-06-27 Koninklijke Philips Electronics N.V. Encapsulation system for controlled release of a bleaching agent
BR112014016810A8 (pt) * 2012-01-06 2017-07-04 Elcelyx Therapeutics Inc composições e métodos para tratamento de distúrbios metabólicos
BR112014021388A2 (pt) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc composições de microbiota e métodos rela-cionados às mesmas
HUE036187T2 (hu) 2012-04-30 2018-06-28 Tillotts Pharma Ag Késleltetett leadású gyógyszerkészítmény
CA2885537C (en) 2012-09-20 2021-11-23 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
WO2015000053A1 (en) 2013-07-03 2015-01-08 Farnum Bryan Christopher Enzyme formulation for use as food supplement
EP3157536A4 (en) 2014-06-20 2018-01-24 Gelesis LLC Methods for treating overweight or obesity
CN104117057B (zh) * 2014-07-09 2017-04-12 广东省医疗器械研究所 一种负载酶的具有释氧功能的水凝胶组合物及其形成的水凝胶
US20160158174A1 (en) 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
EP3285778A2 (en) 2015-04-23 2018-02-28 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
CN107921073B (zh) 2015-06-01 2022-10-18 塞诺生物科学股份有限公司 用于调节肠道微生物群及管理体重的方法和组合物
WO2017174744A1 (en) * 2016-04-07 2017-10-12 University College Dublin, National University Of Ireland, Dublin Treatment of inflammatory bowel disease
CN110520111B (zh) 2016-11-30 2023-12-19 塞诺生物科学股份有限公司 用以管理体重和调节肠道微生物群的药物制剂和方法
GB201707153D0 (en) 2017-05-04 2017-06-21 Univ Ulster Therapy
CN109419807A (zh) 2017-08-22 2019-03-05 萧湘 氧气作为调整肠道菌群的活性成分在制备药物中的用途

Also Published As

Publication number Publication date
MX391477B (es) 2025-03-19
WO2016196440A1 (en) 2016-12-08
MX2017015247A (es) 2018-08-28
EP3302703A4 (en) 2019-07-03
US20260027072A1 (en) 2026-01-29
EP3302703B1 (en) 2021-08-25
US11179357B2 (en) 2021-11-23
US20210161839A1 (en) 2021-06-03
US20210177784A1 (en) 2021-06-17
EP3915552A1 (en) 2021-12-01
CN107921073B (zh) 2022-10-18
US20180147167A1 (en) 2018-05-31
EP3302703A1 (en) 2018-04-11
CN107921073A (zh) 2018-04-17
US11179356B2 (en) 2021-11-23
AU2016271303C1 (en) 2022-04-14
AU2016271303A1 (en) 2017-12-21
US20210169829A1 (en) 2021-06-10
US10945974B2 (en) 2021-03-16
AU2016271303B2 (en) 2021-06-03
MX2021011982A (es) 2021-11-03
ES2898930T3 (es) 2022-03-09
CA2987863A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
MX2022001144A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
GT201200348A (es) Composiciones farmacèuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
MX2019010594A (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX390570B (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
CL2016000397A1 (es) Tratamiento contra el cáncer
CO6602160A2 (es) Terapia de b12 oral
MX376014B (es) Composicion para el cuidado bucal.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
DOP2013000004A (es) Agentes terapeuticos 976